In 2017, the uptake of the biosimilar for infliximab in Canada was still relatively low (2.7% of all infliximab use) compared with the average (35.2%) and median (32.9%) uptake across all OECD countries.
*France, Germany, Italy, Sweden, Switzerland, the United Kingdom, and the United States.
Data source: MIDAS™ Database, prescription retail and hospital markets, 2017, IQVIA. All rights reserved.
Note: The OECD median for 2017 was originally reported as 35.2%. The text has subsequently been revised.